EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment Modifications in Acute Coronary Syndrome Patients Treated with Ticagrelor: Insights from the FORCE-ACS Registry

Niels M R van der Sangen iD, Jaouad Azzahhafi, Dean R P P Chan Pin Yin, Lucas J G Zaaijer, Wout W A van den Broek, Ronald J Walhout, Melvyn Tjon Joe Gin, Ron Pisters, Deborah M Nicastia, Jorina Langerveld, Georgios J Vlachojannis, Rutger J van Bommel und 4 weitere

Thrombosis and Haemostasis · 01.06.2025 · 125 (06) · 597-606

DOI: 10.1055/a-2421-8866 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.06.2025. Verfasst von Niels M R van der Sangen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Ticagrelor, Acute Coronary Syndrome, Platelet Aggregation Inhibitors, Purinergic P2Y Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw, the St. Antonius Research Fund, and AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients presenting with acute coronary syndrome (ACS) are frequently treated with the P2Y12-inhibitor ticagrelor. Some patients prematurely discontinue ticagrelor, but the incidence of reasons for and clinical implications of treatment modification are relatively unknown. Data from 4,278 ACS patients (mean age: 63.6 years, 26.1% women) who were discharged on ticagrelor and enrolled in the FORCE-ACS registry between 2015 and 2020 were used. Treatment modifications were categorized as physician-recommended discontinuation, alteration, interruption, or disruption and occurred in 26.7, 20.1, 2.8, and 3.1% of patients within 12 months of follow-up (Visual Summary). Underlying reasons for treatment modification differed per type of modification. Overall, the rate of ischemic events defined as all-cause death, myocardial infarction, or stroke was 6.6% at 12 months of follow-up. Cox regression analysis using time-updated modification variables as independent variables showed that treatment interruption (adjusted hazard ratio [HR]: 2.93, 95% confidence interval [CI]: 1.48–5.79, p < 0.01) and disruption (adjusted HR: 2.33, 95% CI: 1.07–5.07, p = 0.03) were associated with an increased risk of ischemic events even after adjustment for relevant confounders. Discontinuation and alteration were not associated with increased ischemic risk. In clinical practice, treatment modifications in ACS patients discharged on ticagrelor are common, although type and reasons for modification are heterogeneous. Treatment interruption and disruption are associated with excess cardiovascular risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TicagrelorAcute Coronary SyndromePlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsHumansFemaleMiddle AgedMaleRegistriesAgedTreatment OutcomeMyocardial InfarctionRisk Factors

Substanzen

TicagrelorPlatelet Aggregation InhibitorsPurinergic P2Y Receptor Antagonists

Autor:innen und Institutionen

  • Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
  • Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
  • Department of Cardiology, Hospital Gelderse Vallei, Ede, The Netherlands.
  • Department of Cardiology, Rijnstate Hospital, Arnhem, The Netherlands.
  • Department of Cardiology, Gelre Hospitals, Apeldoorn, The Netherlands.
  • Department of Cardiology, Rivierenland Hospital, Tiel, The Netherlands.

ORCID-Profile: Niels M R van der Sangen

Förderung

  • ZonMw, the St. Antonius Research Fund, and AstraZeneca

Zitieren

APA

van der Sangen, N. M. R., Azzahhafi, J., Chan Pin Yin, D. R. P. P., Zaaijer, L. J. G., van den Broek, W. W. A., Walhout, R. J., Tjon Joe Gin, M., Pisters, R., Nicastia, D. M., Langerveld, J., Vlachojannis, G. J., van Bommel, R. J., Appelman, Y., Henriques, J. P. S., Kikkert, W. J., & Ten Berg, J. M. (2025). Treatment Modifications in Acute Coronary Syndrome Patients Treated with Ticagrelor: Insights from the FORCE-ACS Registry. Thrombosis and Haemostasis, 125(06), 597-606. https://doi.org/10.1055/a-2421-8866

Vancouver

van der Sangen NMR, Azzahhafi J, Chan Pin Yin DRPP, Zaaijer LJG, van den Broek WWA, Walhout RJ, et al. Treatment Modifications in Acute Coronary Syndrome Patients Treated with Ticagrelor: Insights from the FORCE-ACS Registry. Thrombosis and Haemostasis. 2025;125(06):597-606. doi:10.1055/a-2421-8866

BibTeX
@article{vanderSangen2025,
  author = {van der Sangen, Niels M R and Azzahhafi, Jaouad and Chan Pin Yin, Dean R P P and Zaaijer, Lucas J G and van den Broek, Wout W A and Walhout, Ronald J and Tjon Joe Gin, Melvyn and Pisters, Ron and Nicastia, Deborah M and Langerveld, Jorina and Vlachojannis, Georgios J and van Bommel, Rutger J and Appelman, Yolande and Henriques, José P S and Kikkert, Wouter J and Ten Berg, Jurriën M},
  title = {Treatment Modifications in Acute Coronary Syndrome Patients Treated with Ticagrelor: Insights from the FORCE-ACS Registry},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {06},
  pages = {597--606},
  doi = {10.1055/a-2421-8866}
}
Kostenlos starten →